Dossier assessment
Amivantamab (NSCLC, combination with carboplatin and pemetrexed) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Amivantamab (NSCLC, combination with carboplatin and pemetrexed) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Amivantamab (NSCLC, combination with carboplatin and pemetrexed) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations; first-line treatment
Added benefit not proven
Project details
- Project no.
- A25-10
- Commission
- Commission awarded on 22.01.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-10_en
Connected Projects
-
Dossier assessment
Amivantamab (NSCLC) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Amivantamab (NSCLC, first line, combination with lazertinib) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Amivantamab (NSCLC, pretreated) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed